针对嵌合体分子的蛋白质降解市场规模、份额和成长分析：按类型、按适应症、按技术、按应用、按最终用户、按地区 - 2025-2032 年行业预测

2023年，蛋白水解靶向嵌合体分子（PROTAC）的全球市场规模为1.2546亿美元，从2024年的1.3826亿美元增长到2032年的3.007亿美元，预测期（2025-2032）预计复合年增长率为10.2%。

PROTAC（蛋白水解靶向嵌合体）是一种突破性的治疗方法，透过选择性和特异性降解而不是标准抑制来靶向先前「无法治疗」的蛋白质。透过绕过传统的结合限制并利用与不同蛋白质结构域结合的配体，它们有效地结合困难的蛋白质，例如转录因子和激酶。此方法可以更全面、更持续地抑制标靶蛋白。例如，针对雄性激素受体的药物可抑制前列腺癌细胞的增殖，而靶向 BCL-2 的药物可诱导各种癌症的细胞凋亡。儘管取得了有希望的发展，但挑战仍然存在，特别是在设计有效结合的配体和优化药物动力学特性以增强体内性能方面。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

按类型分類的全球蛋白水解靶向嵌合体分子 (PROTAC) 市场规模

• 市场概况
• 小分子PROTAC
• 胜肽PROTAC
• 以蛋白质为基础的 PROTAC

按适应症分類的全球蛋白质降解靶向嵌合体分子 (PROTAC) 市场规模

• 市场概况
• 癌症
• 自体免疫疾病
• 神经退化性疾病

按技术分類的全球蛋白水解靶向嵌合体分子 (PROTAC) 市场规模

• 市场概况
• 双功能性
• 单价

全球蛋白质降解靶向嵌合体分子 (PROTAC) 市场规模（按应用）

• 市场概况
• 肿瘤学
• 神经退化性疾病
• 发炎性疾病

按最终用户分類的全球蛋白水解嵌合体分子 (PROTAC) 市场规模

• 市场概况
• 製药公司
• 学术研究所
• 合约调查机构（Cros）

全球蛋白质降解靶向嵌合体分子（PROTAC）市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• Arvinas（USA）
• C4 Therapeutics（USA）
• Kymera Therapeutics（USA）
• Nurix Therapeutics（USA）
• Bristol Myers Squibb（USA）
• Pfizer（USA）
• Sanofi（France）
• AstraZeneca（UK）
• Roche（Switzerland）
• Olema Pharmaceuticals（USA）
• Radius Health（USA）
• Loxo Oncology（USA）
• Amphista Therapeutics（UK）
• Monte Rosa Therapeutics（USA）
• Dunad Therapeutics（UK）
• Ranok Therapeutics（China）
• Ubiquigent（UK）
• Origami Therapeutics（USA）
• Treeline Biosciences（USA）
• Entact Bio（USA）

结论和建议

Global Proteolysis-targeting chimeric molecules (PROTACs) Market size was valued at USD 125.46 million in 2023 and is poised to grow from USD 138.26 million in 2024 to USD 300.7 million by 2032, growing at a CAGR of 10.2% during the forecast period (2025-2032).

PROTACs (Proteolysis Targeting Chimeras) represent a groundbreaking therapeutic approach, targeting previously "undruggable" proteins through selective and specific degradation rather than standard inhibition. They effectively engage with challenging proteins, such as transcription factors and kinases, by utilizing ligands that bind to distinct protein domains, circumventing traditional binding limitations. This method facilitates a more comprehensive and lasting inhibition of target proteins. Preclinical studies have demonstrated significant efficacy, showing PROTACs' potential in cancer therapies; for instance, one targeting the androgen receptor inhibited prostate cancer cell growth, while another targeting BCL-2 induced apoptosis in various cancers. Despite promising developments, challenges remain, particularly in designing ligands for effective binding and optimizing pharmacokinetic properties for enhanced in vivo performance.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Proteolysis-Targeting Chimeric Molecules (Protacs) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Proteolysis-Targeting Chimeric Molecules (Protacs) Market Segmental Analysis

Global Proteolysis-targeting chimeric molecules (PROTACs) Market is segmented by Type, Indication, Technology, Application, End-User and region. Based on Type, the market is segmented into Small Molecule PROTACs, Peptide PROTACs and Protein-Based PROTACs. Based on Indication, the market is segmented into Cancer, Autoimmune Diseases and Neurodegenerative Disorders. Based on Technology, the market is segmented into Bifunctional and Monovalent. Based on Application, the market is segmented into Oncology, Neurodegenerative Diseases and Inflammatory Diseases. Based on End-User, the market is segmented into Pharmaceutical Companies, Academic and Research Institutions and Contract Research Organizations (Cros). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Proteolysis-Targeting Chimeric Molecules (Protacs) Market

A key driving force behind the advancement of Proteolysis-Targeting Chimeric Molecules (PROTACs) is the growing demand for enhanced target specificity in drug development. Traditional small-molecule drugs typically exhibit a lack of specificity, often affecting multiple proteins and resulting in unintended side effects and potential toxicity. In contrast, PROTACs are meticulously engineered to hone in on a particular protein or even a specific domain within that protein. This heightened level of target specificity significantly mitigates the risk of off-target consequences, thereby improving the safety profile of these molecules and paving the way for innovative treatments for previously challenging diseases.

Restraints in the Global Proteolysis-Targeting Chimeric Molecules (Protacs) Market

One significant challenge facing the Proteolysis-Targeting Chimeric Molecules (PROTACs) market is the complexity of designing and synthesizing compounds that are both effective and safe. Achieving the right balance between the ligands' affinity for their specific targets and the potency of the E3 ligase recruiting ligand is crucial, yet difficult. Multiple factors, including steric hindrance, charge, and solubility, can affect ligand binding affinity. Furthermore, selecting the appropriate E3 ligase is critical, as certain E3 ligases may exhibit promiscuous activity, which can result in undesired off-target effects, complicating the development of reliable PROTAC therapeutics.

Market Trends of the Global Proteolysis-Targeting Chimeric Molecules (Protacs) Market

The Global Proteolysis-Targeting Chimeric Molecules (PROTACs) market is witnessing significant growth, driven by the escalating adoption of this innovative technology in drug discovery and development. By focusing on the degradation of disease-causing proteins rather than mere inhibition, PROTACs present a transformative approach that enhances therapeutic efficacy, particularly for diseases resistant to conventional treatments. As pharmaceutical companies and research institutions intensify their exploration of PROTACs, the market is experiencing a surge in research and development activities. This trend is poised to revolutionize treatment paradigms, attracting attention from investors and stakeholders, further propelling the PROTACs market towards expansive growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by Type & CAGR (2025-2032)

• Market Overview
• Small Molecule PROTACs
• Peptide PROTACs
• Protein-Based PROTACs

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Cancer
• Autoimmune Diseases
• Neurodegenerative Disorders

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Bifunctional
• Monovalent

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology
• Neurodegenerative Diseases
• Inflammatory Diseases

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical Companies
• Academic and Research Institutions
• Contract Research Organizations (Cros)

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size & CAGR (2025-2032)

• North America (Type, Indication, Technology, Application, End-User)
  • US
  • Canada
• Europe (Type, Indication, Technology, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Indication, Technology, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Indication, Technology, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Indication, Technology, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Arvinas (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C4 Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kymera Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nurix Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olema Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Radius Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Loxo Oncology (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amphista Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Monte Rosa Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dunad Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ranok Therapeutics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ubiquigent (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Origami Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Treeline Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Entact Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations